Darunavir

"Darunavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.

Descriptor ID	D000069454
MeSH Number(s)	D02.065.884.438 D02.241.081.251.222 D02.886.590.700.400 D03.383.312.303
Concept/Terms	Darunavir Darunavir Prezista Prezista UIC-94017 UIC-94017 UIC 94017 UIC94017 Darunavir Ethanolate Darunavir Ethanolate Ethanolate, Darunavir TMC 114 TMC 114 114, TMC TMC114 TMC-114

Below are MeSH descriptors whose meaning is more general than "Darunavir".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Amides [D02.065]
Sulfonamides [D02.065.884]
Darunavir [D02.065.884.438]
Carboxylic Acids [D02.241]
Acids, Acyclic [D02.241.081]
Carbamates [D02.241.081.251]
Darunavir [D02.241.081.251.222]
Sulfur Compounds [D02.886]
Sulfones [D02.886.590]
Sulfonamides [D02.886.590.700]
Darunavir [D02.886.590.700.400]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Furans [D03.383.312]
Darunavir [D03.383.312.303]

Below are MeSH descriptors whose meaning is more specific than "Darunavir".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Darunavir" by people in this website by year, and whether "Darunavir" was a major or minor topic of these publications.

Bar chart showing 9 publications over 9 distinct years, with a maximum of 1 publications in 2009 and 2010 and 2012 and 2013 and 2014 and 2015 and 2018 and 2019 and 2025

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2009	0	1	1
2010	0	1	1
2012	0	1	1
2013	0	1	1
2014	0	1	1
2015	0	1	1
2018	1	0	1
2019	1	0	1
2025	0	1	1

Below are the most recent publications written about "Darunavir" by people in Profiles.

Anderson D, Ramgopal M, Hagins DP, Lee J, Simonson RB, Hsu TH, Xu P, Ahmad N, Short WR. DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor-Based Regimen Switch Strategy to Manage Integrase Inhibitor-Related Weight Gain. Clin Infect Dis. 2025 03 17; 80(3):602-612.

View in: PubMed
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV. 2020 01; 7(1):e16-e26.

View in: PubMed
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018 05; 5(5):e211-e220.

View in: PubMed
Sherman EM, Worley MV, Unger NR, Gauthier TP, Schafer JJ. Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection. Clin Ther. 2015 Sep 01; 37(9):1876-93.

View in: PubMed
Flynn P, Komar S, Blanche S, Giaquinto C, Noguera-Julian A, Welch S, Lathouwers E, Van de Casteele T, Kakuda TN, Opsomer M. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-na?ve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE). Pediatr Infect Dis J. 2014 Sep; 33(9):940-5.

View in: PubMed
Squires K, Feinberg J, Bridge DA, Currier J, Ryan R, Seyedkazemi S, Dayaram YK, Mrus J. Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey. AIDS Patient Care STDS. 2013 Jun; 27(6):352-62.

View in: PubMed
Smith KY, Garcia F, Kumar P, Currier JS, Ryan R, Falcon R, Mrus J, Squires K. Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE. J Natl Med Assoc. 2012 Jul-Aug; 104(7-8):366-76.

View in: PubMed
Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010 Sep 21; 153(6):349-57.

View in: PubMed
Blanche S, Bologna R, Cahn P, Rugina S, Flynn P, Fortuny C, Vis P, Sekar V, van Baelen B, Dierynck I, Spinosa-Guzman S. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS. 2009 Sep 24; 23(15):2005-13.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement